
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1340220/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Temperature, Humidity, and Latitude Analysis to Estimate Potential Spread and Seasonality of Coronavirus Disease 2019 (COVID-19). JAMA Network Open, 2020, 3, e2011834.	2.8	496
2	Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2. JAMA - Journal of the American Medical Association, 2021, 325, 1467.	3.8	311
3	Temperature and Latitude Analysis to Predict Potential Spread and Seasonality for COVID-19. SSRN Electronic Journal, 2020, , 3550308.	0.4	288
4	Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study. Science, 2021, 374, 472-478.	6.0	228
5	Virologic Response Following Combined Ledipasvir and Sofosbuvir Administration in Patients With HCV Genotype 1 and HIV Co-infection. JAMA - Journal of the American Medical Association, 2015, 313, 1232.	3.8	186
6	Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E69-78.	3.3	138
7	Structural Definition of an Antibody-Dependent Cellular Cytotoxicity Response Implicated in Reduced Risk for HIV-1 Infection. Journal of Virology, 2014, 88, 12895-12906.	1.5	108
8	Do Biomarkers of Inflammation, Monocyte Activation, and Altered Coagulation Explain Excess Mortality Between HIV Infected and Uninfected People?. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, 206-213.	0.9	95
9	Identification of Near-Pan-neutralizing Antibodies against HIV-1 by Deconvolution of Plasma Humoral Responses. Cell, 2018, 173, 1783-1795.e14.	13.5	80
10	HIV-1 natural viral suppressors: control of viral replication in the absence of therapy. Aids, 2007, 21, 517-519.	1.0	75
11	Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection. Proceedings of the United States of America, 2009, 106, 3952-3957.	3.3	70
12	Performance of nucleocapsid and spike-based SARS-CoV-2 serologic assays. PLoS ONE, 2020, 15, e0237828.	1.1	67
13	Epidemiologic Characteristics and Natural History of HIV-1 Natural Viral Suppressors. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 50, 403-408.	0.9	62
14	SARS-CoV-2 vaccines for all but a single dose for COVID-19 survivors. EBioMedicine, 2021, 68, 103401.	2.7	58
15	Role of miR-2392 in driving SARS-CoV-2 infection. Cell Reports, 2021, 37, 109839.	2.9	52
16	Crimean–Congo hemorrhagic fever in Iran. Antiviral Research, 2013, 100, 20-28.	1.9	51
17	Cocrystal Structures of Antibody N60-i3 and Antibody JR4 in Complex with gp120 Define More Cluster A Epitopes Involved in Effective Antibody-Dependent Effector Function against HIV-1. Journal of Virology, 2015, 89, 8840-8854.	1.5	51
18	Merits of FDG PET/CT and Functional MolecularÂlmaging Over Anatomic ImagingÂWithÂEchocardiography and CTÂAngiography for the Diagnosis of CardiacÂDeviceÂInfections. JACC: Cardiovascular Imaging, 2018, 11, 1679-1691.	2.3	48

#	Article	IF	CITATIONS
19	Natural viral suppressors of HIV-1 have a unique capacity to maintain $\hat{I}^{3}\hat{I}$ T cells. Aids, 2009, 23, 1955-1964.	1.0	43
20	Chronic immune activation and decreased CD4 cell counts associated with hepatitis C infection in HIV-1 natural viral suppressors. Aids, 2012, 26, 1879-1884.	1.0	43
21	Maintenance of HIV-Specific Memory B-Cell Responses in Elite Controllers Despite Low Viral Burdens. Journal of Infectious Diseases, 2016, 214, 390-398.	1.9	43
22	The history of facial palsy and spasm. Neurology, 2011, 77, 174-178.	1.5	38
23	Soluble factors from T cells inhibiting X4 strains of HIV are a mixture of β chemokines and RNases. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 5411-5416.	3.3	38
24	Increased expression of suppressor of cytokine signaling-1 (SOCS-1): A mechanism for dysregulated T helper-1 responses in HIV-1 disease. Virology, 2009, 385, 126-133.	1.1	33
25	Hepatitis C infection in HIV-1 natural viral suppressors. Aids, 2010, 24, 1689-1695.	1.0	32
26	Correlation Between Circulating HIV-1 RNA and Broad HIV-1 Neutralizing Antibody Activity. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, 9-15.	0.9	31
27	Medical Versus Medical and Surgical Treatment for Brucella Endocarditis. Annals of Thoracic Surgery, 2012, 94, 2141-2146.	0.7	30
28	Elevated hypermutation levels in HIV-1 natural viral suppressors. Virology, 2013, 443, 306-312.	1.1	30
29	Epitope target structures of Fc-mediated effector function during HIV-1 acquisition. Current Opinion in HIV and AIDS, 2014, 9, 263-270.	1.5	30
30	Impact of Persistent HIV Replication on CD4 Negative Vγ2Vδ2 T Cells. Journal of Infectious Diseases, 2012, 205, 1448-1455.	1.9	27
31	Rate of re-positive RT-PCR test among patients recovered from COVID-19. Biochemia Medica, 2020, 30, 355-356.	1.2	27
32	Akhawayni and the First Fever Curve. Clinical Infectious Diseases, 2012, 55, 976-980.	2.9	24
33	A Czech Researcher and Pneumocystis. Clinical Infectious Diseases, 2004, 39, 218-218.	2.9	22
34	Ibn Sina and the Clinical Trial. Annals of Internal Medicine, 2009, 150, 640.	2.0	21
35	Successful transfer of anti–SARS-CoV-2 immunity using convalescent plasma in an MM patient with hypogammaglobulinemia and COVID-19. Blood Advances, 2020, 4, 4864-4868.	2.5	20
36	Broadly Neutralizing Antibodies against HIV: Back to Blood. Trends in Molecular Medicine, 2019, 25, 228-240.	3.5	19

#	Article	IF	CITATIONS
37	Emergence of whooping cough: notes from three early epidemics in Persia. Lancet Infectious Diseases, The, 2015, 15, 1480-1484.	4.6	18
38	λ Light Chain Bias Associated With Enhanced Binding and Function of Anti-HIV Env Glycoprotein Antibodies. Journal of Infectious Diseases, 2016, 213, 156-164.	1.9	18
39	COVID-19 Infection Among Women in Iran Exposed vs Unexposed to Children Who Received Attenuated Poliovirus Used in Oral Polio Vaccine. JAMA Network Open, 2021, 4, e2135044.	2.8	18
40	Use of oral polio vaccine and the incidence of COVID-19 in the world. PLoS ONE, 2022, 17, e0265562.	1.1	17
41	IL28B Genotype Does Not Correlate with HIV Control in African Americans. Clinical and Translational Science, 2011, 4, 282-284.	1.5	15
42	Portal Hypertension Secondary to Isolated Liver Tuberculosis. American Journal of Tropical Medicine and Hygiene, 2012, 87, 162-164.	0.6	14
43	Signature Biochemical Properties of Broadly Cross-Reactive HIV-1 Neutralizing Antibodies in Human Plasma. Journal of Virology, 2012, 86, 5014-5025.	1.5	12
44	Early descriptions of Grisel's syndrome. Child's Nervous System, 2013, 29, 359-360.	0.6	12
45	Long-term follow-up of elite controllers. Medicine (United States), 2017, 96, e7348.	0.4	10
46	Temperature Regulation and the Pathogenesis of Fever. , 2015, , 708-720.e4.		9
47	Tenofovir and Abacavir Combination Therapy: Lessons Learned from an Urban Clinic Population. AIDS Patient Care and STDs, 2007, 21, 240-246.	1.1	7
48	Altered T-cell subsets in HIV-1 natural viral suppressors (elite controllers) with hepatitis C infection. Aids, 2013, 27, 1989-1992.	1.0	7
49	Targeted Bacteria-Specific 18F-Fluoro-Maltohexaose But Not FDGÂPET Distinguishes Infection FromÂInflammation. JACC: Cardiovascular Imaging, 2019, 12, 887-889.	2.3	7
50	Original Research: Risk Factors for Mortality from Primary Cryptococcosis in Patients with HIV. Postgraduate Medicine, 2009, 121, 107-113.	0.9	6
51	CoughNet-V2: A Scalable Multimodal DNN Framework for Point-of-Care Edge Devices to Detect Symptomatic COVID-19 Cough. , 2022, , .		5
52	Production of a chimeric protein and its potential application in sero-diagnosis of Mycoplasma hominis infection. Journal of Microbiological Methods, 2018, 144, 186-191.	0.7	4
53	Provir/Latitude 45 study: A step towards a multi-epitopic CTL vaccine designed on archived HIV-1 DNA and according to dominant HLA I alleles. PLoS ONE, 2019, 14, e0212347.	1.1	4
54	Near-Pan-neutralizing, Plasma Deconvoluted Antibody N49P6 Mimics Host Receptor CD4 in Its Quaternary Interactions with the HIV-1 Envelope Trimer. MBio, 2021, 12, e0127421.	1.8	4

#	Article	IF	CITATIONS
55	Abdominal Pain and Bacterial Meningitis in a Previously Healthy Young Adult. Clinical Infectious Diseases, 2008, 46, 1479-1480.	2.9	3
56	Rational Engraftment of Quaternary-Interactive Acidic Loops for Anti-HIV-1 Antibody Improvement. Journal of Virology, 2021, 95, .	1.5	3
57	Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trial. Vaccine, 2021, 39, 3879-3891.	1.7	3
58	Single-Dose Ad26.COV2.S Vaccine—Room for Improvement. JAMA Network Open, 2021, 4, e2133012.	2.8	3
59	Urine Vancomycin Level as a Method for Drug Monitoring in Patients With Normal and Decreased Kidney Function. Iranian Journal of Kidney Diseases, 2017, 11, 367-370.	0.1	3
60	Acute Necrotizing Pneumonia in a Previously Healthy Young Adult. Clinical Infectious Diseases, 2008, 46, 266-267.	2.9	2
61	Long-term Nonprogressive Disease Among Individuals With Untreated HIV Infection. JAMA - Journal of the American Medical Association, 2010, 304, 1784.	3.8	2
62	Combined cART including Tenofovir Disoproxil, Emtricitabine, and Dolutegravir has potent therapeutic effects in HIV-1 infected humanized mice. Journal of Translational Medicine, 2021, 19, 453.	1.8	2
63	Variability of CD4+ Cell Counts in HIV-1–Uninfected Volunteers Who Are Eligible for a Phase I HIV Vaccine Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 84, 37-44.	0.9	1
64	Determining the SARS-CoV-2 serological immunoassay test performance indices based on the test results frequency distribution. Biochemia Medica, 2022, 32, 217-223.	1.2	1
65	A Young Woman with Diffuse Skin Lesions. Clinical Infectious Diseases, 2010, 51, 195-196.	2.9	0
66	A Young Woman with Diffuse Skin Lesions. Clinical Infectious Diseases, 2010, 51, 248-249.	2.9	0
67	Donor Specific Mesenchymal Stem Cells MSCs Transfusion for Desensitization of Resistant Positive Donor Specific Lymphocyte Cross Match and Reduction of Panel Reactive Antibodies PRA. Report of 4 Cases Transplantation, 2012, 94, 1062.	0.5	Ο
68	Donor Specific Mesenchymal Stem Cells MSCs Transfusion for Desensitization of Resistant Positive Donor Specific Lymphocyte Cross Match and Reduction of Panel Reactive Antibodies PRA. Report of 4 Cases Transplantation, 2012, 94, 233.	0.5	0
69	Reply to Hartjen et al. Journal of Infectious Diseases, 2013, 208, 184-184.	1.9	Ο
70	The "100 Days Cough―Was Not Originally Whooping Cough. Open Forum Infectious Diseases, 2016, 3, ofw069.	0.4	0
71	Pathogenesis of Fever. , 2017, , 605-610.e1.		0
72	Diagnostic Value of the Leukocyte Esterase Test for Early Detection of Pleocytosis in Cerebrospinal Fluid of Patients with Suspected Acute Bacterial Meningitis. Infectious Disorders - Drug Targets, 2018, 18, 29-34.	0.4	0

#	Article	IF	CITATIONS
73	2838. Safety and Immunogenicity of a gp120-CD4 Chimeric Subunit Vaccine: A Phase 1a Randomized Controlled Trial. Open Forum Infectious Diseases, 2019, 6, S65-S66.	0.4	0